WEST VIRGINIA LEGISLATURE 2017 REGULAR SESSION

Committee Substitute

for

Senate Bill 526

By SENATOR TAKUBO

[Originating in the Committee on Banking and

Insurance; reported on March 23, 2017]

A BILL to amend and reenact §5-16-7 of the Code of West Virginia, 1931, as amended; to amend said code by adding thereto a new section, designated §5-16B-6f; to amend said code by adding thereto a new section, designated §9-5-25; to amend said code by adding thereto a new section, designated §33-15-4p; to amend said code by adding thereto a new section, designated §33-16-3bb; to amend said code by adding thereto a new section, designated §33-24-7q; to amend said code by adding thereto a new section, designated §33-25-8n; and to amend said code by adding thereto a new section, designated §33-25A-8p, all relating to mandatory insurance coverage for medical foods for inherited enzymatic disorders; providing a list of diagnosed conditions for which insurance coverage should extend; providing that coverage extends to medically necessary foods for home use when prescribed by a physician; defining terms; and providing for exclusions.

Be it enacted by the Legislature of West Virginia:

That §5-16-7 of the Code of West Virginia, 1931, as amended, be amended and reenacted; that said code be amended by adding thereto a new section, designated §5-16B-6f; that said code be amended by adding thereto a new section, designated §9-5-25; that said code be amended by adding thereto a new section, designated §33-15-4p; that said code be amended by adding thereto a new section, designated §33-16-3bb; that said code be amended by adding thereto a new section, designated §33-24-7q; that said code be amended by adding thereto a new section, designated §33-25-8n; and that said code be amended by adding thereto a new section, designated §33-25A-8p, all to read as follows:

CHAPTER 5. GENERAL POWERS AND AUTHORITY OF THE
GOVERNOR, SECRETARY OF STATE AND ATTORNEY GENERAL;
BOARD OF PUBLIC WORKS; MISCELLANEOUS AGENCIES,
COMMISSIONS, OFFICES, PROGRAMS, ETC.

ARTICLE 16. WEST VIRGINIA PUBLIC EMPLOYEES INSURANCE ACT.

- §5-16-7. Authorization to establish group hospital and surgical insurance plan, group major medical insurance plan, group prescription drug plan and group life and accidental death insurance plan; rules for administration of plans; mandated benefits; what plans may provide; optional plans; separate rating for claims experience purposes.
- (a) The agency shall establish a group hospital and surgical insurance plan or plans, a group prescription drug insurance plan or plans, a group major medical insurance plan or plans and a group life and accidental death insurance plan or plans for those employees herein made eligible and establish and promulgate rules for the administration of these plans subject to the limitations contained in this article. These plans shall include:
- (1) Coverages and benefits for x-ray and laboratory services in connection with mammograms when medically appropriate and consistent with current guidelines from the United States Preventive Services Task Force; pap smears, either conventional or liquid-based cytology, whichever is medically appropriate, and consistent with the current guidelines from either the United States Preventive Services Task Force or The American College of Obstetricians and Gynecologists; and a test for the human papilloma virus (HPV) when medically appropriate and consistent with current guidelines from either the United States Preventive Services Task Force or The American College of Obstetricians and Gynecologists, when performed for cancer screening or diagnostic services on a woman age eighteen or over;
 - (2) Annual checkups for prostate cancer in men age fifty and over;
- (3) Annual screening for kidney disease as determined to be medically necessary by a physician using any combination of blood pressure testing, urine albumin or urine protein testing and serum creatinine testing as recommended by the National Kidney Foundation;
- (4) For plans that include maternity benefits, coverage for inpatient care in a duly licensed health care facility for a mother and her newly born infant for the length of time which the attending

- physician considers medically necessary for the mother or her newly born child. No plan may deny payment for a mother or her newborn child prior to forty-eight hours following a vaginal delivery or prior to ninety-six hours following a caesarean section delivery if the attending physician considers discharge medically inappropriate;
- (5) For plans which provide coverages for post-delivery care to a mother and her newly born child in the home, coverage for inpatient care following childbirth as provided in subdivision (4) of this subsection if inpatient care is determined to be medically necessary by the attending physician. These plans may include, among other things, medicines, medical equipment, prosthetic appliances and any other inpatient and outpatient services and expenses considered appropriate and desirable by the agency; and
 - (6) Coverage for treatment of serious mental illness:
- (A) The coverage does not include custodial care, residential care or schooling. For purposes of this section, "serious mental illness" means an illness included in the American Psychiatric Association's diagnostic and statistical manual of mental disorders, as periodically revised, under the diagnostic categories or subclassifications of: (i) Schizophrenia and other psychotic disorders; (ii) bipolar disorders; (iii) depressive disorders; (iv) substance-related disorders with the exception of caffeine-related disorders and nicotine-related disorders; (v) anxiety disorders; and (vi) anorexia and bulimia. With regard to a covered individual who has not yet attained the age of nineteen years, "serious mental illness" also includes attention deficit hyperactivity disorder, separation anxiety disorder and conduct disorder.
- (B) Notwithstanding any other provision in this section to the contrary, if the agency demonstrates that its total costs for the treatment of mental illness for any plan exceeds two percent of the total costs for such plan in any experience period, then the agency may apply whatever additional cost-containment measures may be necessary in order to maintain costs below two percent of the total costs for the plan for the next experience period. These measures may include, but are not limited to, limitations on inpatient and outpatient benefits.

- (C) The agency shall not discriminate between medical-surgical benefits and mental health benefits in the administration of its plan. With regard to both medical-surgical and mental health benefits, it may make determinations of medical necessity and appropriateness and it may use recognized health care quality and cost management tools including, but not limited to, limitations on inpatient and outpatient benefits, utilization review, implementation of cost-containment measures, preauthorization for certain treatments, setting coverage levels, setting maximum number of visits within certain time periods, using capitated benefit arrangements, using fee-for-service arrangements, using third-party administrators, using provider networks and using patient cost sharing in the form of copayments, deductibles and coinsurance.
- (7) Coverage for general anesthesia for dental procedures and associated outpatient hospital or ambulatory facility charges provided by appropriately licensed health care individuals in conjunction with dental care if the covered person is:
- (A) Seven years of age or younger or is developmentally disabled and is an individual for whom a successful result cannot be expected from dental care provided under local anesthesia because of a physical, intellectual or other medically compromising condition of the individual and for whom a superior result can be expected from dental care provided under general anesthesia;
- (B) A child who is twelve years of age or younger with documented phobias or with documented mental illness and with dental needs of such magnitude that treatment should not be delayed or deferred and for whom lack of treatment can be expected to result in infection, loss of teeth or other increased oral or dental morbidity and for whom a successful result cannot be expected from dental care provided under local anesthesia because of such condition and for whom a superior result can be expected from dental care provided under general anesthesia.
- (8)(A) Any plan issued or renewed on or after January 1, 2012, shall include coverage for diagnosis, evaluation and treatment of autism spectrum disorder in individuals ages eighteen months to eighteen years. To be eligible for coverage and benefits under this subdivision, the individual must be diagnosed with autism spectrum disorder at age eight or younger. Such plan

shall provide coverage for treatments that are medically necessary and ordered or prescribed by a licensed physician or licensed psychologist and in accordance with a treatment plan developed from a comprehensive evaluation by a certified behavior analyst for an individual diagnosed with autism spectrum disorder.

- (B) The coverage shall include, but not be limited to, applied behavior analysis which shall be provided or supervised by a certified behavior analyst. The annual maximum benefit for applied behavior analysis required by this subdivision shall be in an amount not to exceed \$30,000 per individual for three consecutive years from the date treatment commences. At the conclusion of the third year, coverage for applied behavior analysis required by this subdivision shall be in an amount not to exceed \$2,000 per month, until the individual reaches eighteen years of age, as long as the treatment is medically necessary and in accordance with a treatment plan developed by a certified behavior analyst pursuant to a comprehensive evaluation or reevaluation of the individual. This subdivision does not limit, replace or affect any obligation to provide services to an individual under the Individuals with Disabilities Education Act, 20 U.S.C. 1400 et seq., as amended from time to time or other publicly funded programs. Nothing in this subdivision requires reimbursement for services provided by public school personnel.
- (C) The certified behavior analyst shall file progress reports with the agency semiannually. In order for treatment to continue, the agency must receive objective evidence or a clinically supportable statement of expectation that:
 - (i) The individual's condition is improving in response to treatment:
 - (ii) A maximum improvement is yet to be attained; and
- (iii) There is an expectation that the anticipated improvement is attainable in a reasonable and generally predictable period of time.
- (D) On or before January 1 each year, the agency shall file an annual report with the Joint Committee on Government and Finance describing its implementation of the coverage provided pursuant to this subdivision. The report shall include, but not be limited to, the number of

individuals in the plan utilizing the coverage required by this subdivision, the fiscal and administrative impact of the implementation and any recommendations the agency may have as to changes in law or policy related to the coverage provided under this subdivision. In addition, the agency shall provide such other information as required by the Joint Committee on Government and Finance as it may request.

- (E) For purposes of this subdivision, the term:
- (i) "Applied behavior analysis" means the design, implementation and evaluation of environmental modifications using behavioral stimuli and consequences in order to produce socially significant improvement in human behavior and includes the use of direct observation, measurement and functional analysis of the relationship between environment and behavior.
- (ii) "Autism spectrum disorder" means any pervasive developmental disorder including autistic disorder, Asperger's Syndrome, Rett Syndrome, childhood disintegrative disorder or Pervasive Development Disorder as defined in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association.
- (iii) "Certified behavior analyst" means an individual who is certified by the Behavior Analyst Certification Board or certified by a similar nationally recognized organization.
- (iv) "Objective evidence" means standardized patient assessment instruments, outcome measurements tools or measurable assessments of functional outcome. Use of objective measures at the beginning of treatment, during and after treatment is recommended to quantify progress and support justifications for continued treatment. The tools are not required but their use will enhance the justification for continued treatment.
- (F) To the extent that the application of this subdivision for autism spectrum disorder causes an increase of at least one percent of actual total costs of coverage for the plan year, the agency may apply additional cost containment measures.
- (G) To the extent that the provisions of this subdivision require benefits that exceed the essential health benefits specified under section 1302(b) of the Patient Protection and Affordable

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Care Act, Pub. L. No. 111-148, as amended, the specific benefits that exceed the specified
essential health benefits shall not be required of insurance plans offered by the Public Employees
Insurance Agency.

(9) For plans that include maternity benefits, coverage for the same maternity benefits for all individuals participating in or receiving coverage under plans that are issued or renewed on or after January 1, 2014: *Provided,* That to the extent that the provisions of this subdivision require benefits that exceed the essential health benefits specified under section 1302(b) of the Patient Protection and Affordable Care Act, Pub. L. No. 111-148, as amended, the specific benefits that exceed the specified essential health benefits shall not be required of a health benefit plan when the plan is offered in this state.

(10) (A) A policy, plan or contract that is issued or renewed on or after January 1, 2018, and that is subject to this section shall provide coverage for inherited enzymatic disorders caused by single gene defects involved in the metabolism of amino, organic and fatty acids as well as severe protein allergic conditions. This includes the following conditions if diagnosed as related to the disorder by a physician licensed to practice in this state pursuant to either article three or fourteen of chapter thirty of this code:

- (i) Phenylketonuria;
- 142 (ii) Maternal phenylketonuria;
- 143 (iii) Maple syrup urine disease;
- 144 (iv) Tyrosinemia;
- 145 (v) Homocystinuria;
- 146 (vi) Histidinemia;
- 147 (vii) Urea cycle disorders;
- 148 (viii) Hyperlysinemia;
- 149 (ix) Glutaric acidemias;
- 150 (x) Methylmalonic acidemia;

151	(xi) Propionic academia;
152	(xii) Immunoglobulin E and Nonimmunoglobulin E-medicated allergies to multiple food
153	proteins;
154	(xiii) Severe food protein induced enterocolitis syndrome;
155	(xiv) Eosinophilic disorders as evidenced by the results of a biopsy; and
156	(xv) Impaired absorption of nutrients caused by disorders affecting the absorptive surface,
157	function, length and motility of the gastrointestinal tract.
158	(B) The coverage required by paragraph (A) of this subdivision is for medical foods for
159	home use for which a physician has issued a prescription and has declared them to be medically
160	necessary.
161	(C) For purposes of this subdivision, medically necessary foods or medical foods shall
162	mean prescription metabolic formulas and their modular counterparts and amino acid-based
163	elemental formulas obtained through a pharmacy: Provided, That these foods are specifically
164	designated and manufactured for the treatment on inherited enzymatic disorders caused by single
165	gene defects involved in the metabolism of amino, organic and fatty acids and for severe allergic
166	conditions.
167	(D) The provisions of this subdivision shall not apply to persons diagnosed with cystic
168	fibrosis or persons with an intolerance for lactose or soy.
169	(b) The agency shall, with full authorization, make available to each eligible employee, at
170	full cost to the employee, the opportunity to purchase optional group life and accidental death
171	insurance as established under the rules of the agency. In addition, each employee is entitled to
172	have his or her spouse and dependents, as defined by the rules of the agency, included in the
173	optional coverage, at full cost to the employee, for each eligible dependent.
174	(c) The finance board may cause to be separately rated for claims experience purposes:
175	(1) All employees of the State of West Virginia;
176	(2) All teaching and professional employees of state public institutions of higher education

179

180

181

182

183

184

185

186

1

2

3

4

5

6

177 and county boards of education:

- (3) All nonteaching employees of the Higher Education Policy Commission, West Virginia Council for Community and Technical College Education and county boards of education; or
 - (4) Any other categorization which would ensure the stability of the overall program.
- (d) The agency shall maintain the medical and prescription drug coverage for Medicare eligible retirees by providing coverage through one of the existing plans or by enrolling the Medicare eligible retired employees into a Medicare specific plan, including, but not limited to, the Medicare/Advantage Prescription Drug Plan. If a Medicare specific plan is no longer available or advantageous for the agency and the retirees, the retirees remain eligible for coverage through the agency.

ARTICLE 16B. WEST VIRGINIA CHILDRENS HEALTH INSURANCE PROGRAM. §5-16B-6f. Coverage for inherited enzymatic disorders.

- (a) A policy, plan or contract that is issued or renewed on or after January 1, 2018, and that is subject to this section shall provide coverage for inherited enzymatic disorders caused by single gene defects involved in the metabolism of amino, organic and fatty acids as well as severe protein allergic conditions. This includes the following conditions if diagnosed as related to the disorder by a physician licensed to practice in this state pursuant to either article three or fourteen of chapter thirty of this code:
- 7 (1) Phenylketonuria;
- 8 (2) Maternal phenylketonuria;
- 9 (3) Maple syrup urine disease;
- 10 (4) Tyrosinemia;
- 11 (5) Homocystinuria;
- 12 (6) Histidinemia;
- 13 (7) Urea cycle disorders;
- 14 (8) Hyperlysinemia;

2

15	(9) Glutaric acidemias;
16	(10) Methylmalonic acidemia;
17	(11) Propionic academia;
18	(12) Immunoglobulin E and Nonimmunoglobulin E-medicated allergies to multiple food
19	proteins;
20	(13) Severe food protein induced enterocolitis syndrome:
21	(14) Eosinophilic disorders as evidenced by the results of a biopsy; and
22	(15) Impaired absorption of nutrients caused by disorders affecting the absorptive surface.
23	function, length and motility of the gastrointestinal tract.
24	(b) The coverage required by subsection (a) of this section is for medical foods for home
25	use for which a physician has issued a prescription and has declared them to be medically
26	necessary.
27	(c) For purposes of this section, medically necessary foods or medical foods shall mean
28	prescription metabolic formulas and their modular counterparts and amino acid-based elemental
29	formulas obtained through a pharmacy: Provided, That these foods are specifically designated
30	and manufactured for the treatment on inherited enzymatic disorders caused by single gene
31	defects involved in the metabolism of amino, organic and fatty acids and for severe allergic
32	conditions.
33	(d) The provisions of this section shall not apply to persons diagnosed with cystic fibrosis
34	or persons with an intolerance for lactose or soy.
	CHAPTER 9. HUMAN SERVICES.
	ARTICLE 5. MISCELLANEOUS PROVISIONS.
	§9-5-25. Coverage for inherited enzymatic disorders.
1	(a) A policy, plan or contract that is issued or renewed on or after January 1, 2018, and

10

that is subject to this section shall provide coverage for inherited enzymatic disorders caused by

3	single gene defects involved in the metabolism of amino, organic and fatty acids as well as severe
4	protein allergic conditions. This includes the following conditions if diagnosed as related to the
5	disorder by a physician licensed to practice in this state pursuant to either article three or fourteen
6	of chapter thirty of this code:
7	(1) Phenylketonuria;
8	(2) Maternal phenylketonuria;
9	(3) Maple syrup urine disease;
10	(4) Tyrosinemia;
11	(5) Homocystinuria;
12	(6) Histidinemia;
13	(7) Urea cycle disorders;
14	(8) Hyperlysinemia;
15	(9) Glutaric acidemias;
16	(10) Methylmalonic acidemia;
17	(11) Propionic academia;
18	(12) Immunoglobulin E and Nonimmunoglobulin E-medicated allergies to multiple food
19	proteins;
20	(13) Severe food protein induced enterocolitis syndrome;
21	(14) Eosinophilic disorders as evidenced by the results of a biopsy; and
22	(15) Impaired absorption of nutrients caused by disorders affecting the absorptive surface,
23	function, length and motility of the gastrointestinal tract.
24	(b) The coverage required by subsection (a) of this section is for medical foods for
25	home use for which a physician has issued a prescription and has declared them to be medically
26	necessary.
27	(c) For purposes of this section, medically necessary foods or medical foods shall mean
28	prescription metabolic formulas and their modular counterparts and amino acid-based elemental

- formulas obtained through a pharmacy: *Provided*, That these foods are specifically designated
 and manufactured for the treatment on inherited enzymatic disorders caused by single gene
 defects involved in the metabolism of amino, organic and fatty acids and for severe allergic
 conditions.
- (d) The provisions of this section shall not apply to persons diagnosed with cystic fibrosis
 or persons with an intolerance for lactose or soy.

CHAPTER 33. INSURANCE.

ARTICLE 15. ACCIDENT AND SICKNESS INSURANCE.

§33-15-4p. Coverage for inherited enzymatic disorders.

- (a) A policy, plan or contract that is issued or renewed on or after January 1, 2018, and
 that is subject to this section shall provide coverage for inherited enzymatic disorders caused by
 single gene defects involved in the metabolism of amino, organic and fatty acids as well as severe
 protein allergic conditions. This includes the following conditions if diagnosed as related to the
 disorder by a physician licensed to practice in this state pursuant to either article three or fourteen
 of chapter thirty of this code:
- 7 (1) Phenylketonuria;
- 8 (2) Maternal phenylketonuria;
- 9 (3) Maple syrup urine disease;
- 10 (4) Tyrosinemia;
- 11 (5) Homocystinuria;
- 12 <u>(6) Histidinemia;</u>
- 13 (7) Urea cycle disorders;
- 14 (8) Hyperlysinemia;
- 15 (9) Glutaric acidemias;
- 16 (10) Methylmalonic acidemia;

17	(11) Propionic academia;
18	(12) Immunoglobulin E and Nonimmunoglobulin E-medicated allergies to multiple food
19	proteins;
20	(13) Severe food protein induced enterocolitis syndrome;
21	(14) Eosinophilic disorders as evidenced by the results of a biopsy; and
22	(15) Impaired absorption of nutrients caused by disorders affecting the absorptive surface,
23	function, length and motility of the gastrointestinal tract.
24	(b) The coverage required by subsection (a) of this section is for medical foods for home
25	use for which a physician has issued a prescription and has declared them to be medically
26	necessary.
27	(c) For purposes of this section, medically necessary foods or medical foods shall mean
28	prescription metabolic formulas and their modular counterparts and amino acid-based elemental
29	formulas obtained through a pharmacy: Provided, That these foods are specifically designated
30	and manufactured for the treatment on inherited enzymatic disorders caused by single gene
31	defects involved in the metabolism of amino, organic and fatty acids and for severe allergic
32	conditions.
33	(d) The provisions of this section shall not apply to persons diagnosed with cystic fibrosis
34	or persons with an intolerance for lactose or soy.
	ARTICLE 16. GROUP ACCIDENT AND SICKNESS INSURANCE.
	§33-16-3bb. Coverage for inherited enzymatic disorders.
1	(a) A policy, plan or contract that is issued or renewed on or after January 1, 2018, and
2	that is subject to this section shall provide coverage for inherited enzymatic disorders caused by
3	single gene defects involved in the metabolism of amino, organic and fatty acids as well as severe
4	protein allergic conditions. This includes the following conditions if diagnosed as related to the
5	disorder by a physician licensed to practice in this state pursuant to either article three or fourteen
6	of chapter thirty of this code:

7	(1) Phenylketonuria;
8	(2) Maternal phenylketonuria;
9	(3) Maple syrup urine disease;
10	(4) Tyrosinemia;
11	(5) Homocystinuria;
12	(6) Histidinemia;
13	(7) Urea cycle disorders;
14	(8) Hyperlysinemia:
15	(9) Glutaric acidemias;
16	(10) Methylmalonic acidemia;
17	(11) Propionic academia;
18	(12) Immunoglobulin E and Nonimmunoglobulin E-medicated allergies to multiple food
19	proteins;
20	(13) Severe food protein induced enterocolitis syndrome;
21	(14) Eosinophilic disorders as evidenced by the results of a biopsy; and
22	(15) Impaired absorption of nutrients caused by disorders affecting the absorptive surface,
23	function, length and motility of the gastrointestinal tract.
24	(b) The coverage required by subsection (a) of this section is for medical foods for home
25	use for which a physician has issued a prescription and has declared them to be medically
26	necessary.
27	(c) For purposes of this section, medically necessary foods or medical foods shall mean
28	prescription metabolic formulas and their modular counterparts and amino acid-based elemental
29	formulas obtained through a pharmacy: Provided, That these foods are specifically designated
30	and manufactured for the treatment on inherited enzymatic disorders caused by single gene
31	defects involved in the metabolism of amino, organic and fatty acids and for severe allergic
32	conditions.

(d) The provisions of this section shall not apply to persons diagnosed with cystic fibrosis
 or persons with an intolerance for lactose or soy.

ARTICLE 24. HOSPITAL MEDICAL AND DENTAL CORPORATIONS.

§33-24-7q. Coverage for inherited enzymatic disorders.

1 (a) A policy, plan or contract that is issued or renewed on or after January 1, 2018, and 2 that is subject to this section shall provide coverage for inherited enzymatic disorders caused by 3 single gene defects involved in the metabolism of amino, organic and fatty acids as well as severe 4 protein allergic conditions. This includes the following conditions if diagnosed as related to the 5 disorder by a physician licensed to practice in this state pursuant to either article three or fourteen 6 of chapter thirty of this code: 7 (1) Phenylketonuria; 8 (2) Maternal phenylketonuria; (3) Maple syrup urine disease; 9 10 (4) Tyrosinemia; 11 (5) Homocystinuria; 12 (6) Histidinemia; 13 (7) Urea cycle disorders: 14 (8) Hyperlysinemia; 15 (9) Glutaric acidemias; 16 (10) Methylmalonic acidemia; 17 (11) Propionic academia; (12) Immunoglobulin E and Nonimmunoglobulin E-medicated allergies to multiple food 18 19 proteins; 20 (13) Severe food protein induced enterocolitis syndrome; 21 (14) Eosinophilic disorders as evidenced by the results of a biopsy; and 22 (15) Impaired absorption of nutrients caused by disorders affecting the absorptive surface,

23	function, length and motility of the gastrointestinal tract.
24	(b) The coverage required by subsection (a) of this section is for medical foods for home
25	use for which a physician has issued a prescription and has declared them to be medically
26	necessary.
27	(c) For purposes of this section, medically necessary foods or medical foods shall mean
28	prescription metabolic formulas and their modular counterparts and amino acid-based elemental
29	formulas obtained through a pharmacy: Provided, That these foods are specifically designated
30	and manufactured for the treatment on inherited enzymatic disorders caused by single gene
31	defects involved in the metabolism of amino, organic and fatty acids and for severe allergic
32	conditions.
33	(d) The provisions of this section shall not apply to persons diagnosed with cystic fibrosis
34	or persons with an intolerance for lactose or soy.

ARTICLE 25. HEALTHCARE CORPORATION.

§33-25-8n. Coverage for inherited enzymatic disorders.

1 (a) A policy, plan or contract that is issued or renewed on or after January 1, 2018, and 2 that is subject to this section shall provide coverage for inherited enzymatic disorders caused by 3 single gene defects involved in the metabolism of amino, organic and fatty acids as well as severe 4 protein allergic conditions. This includes the following conditions if diagnosed as related to the 5 disorder by a physician licensed to practice in this state pursuant to either article three or fourteen 6 of chapter thirty of this code: 7 (1) Phenylketonuria; 8 (2) Maternal phenylketonuria; 9 (3) Maple syrup urine disease; 10 (4) Tyrosinemia; 11 (5) Homocystinuria; 12 (6) Histidinemia;

13	(7) Urea cycle disorders;
14	(8) Hyperlysinemia;
15	(9) Glutaric acidemias;
16	(10) Methylmalonic acidemia;
17	(11) Propionic academia;
18	(12) Immunoglobulin E and Nonimmunoglobulin E-medicated allergies to multiple food
19	proteins;
20	(13) Severe food protein induced enterocolitis syndrome;
21	(14) Eosinophilic disorders as evidenced by the results of a biopsy; and
22	(15) Impaired absorption of nutrients caused by disorders affecting the absorptive surface,
23	function, length and motility of the gastrointestinal tract.
24	(b) The coverage required by subsection (a) of this section is for medical foods for home
25	use for which a physician has issued a prescription and has declared them to be medically
26	necessary.
27	(c) For purposes of this section, medically necessary foods or medical foods shall mean
28	prescription metabolic formulas and their modular counterparts and amino acid-based elemental
29	formulas obtained through a pharmacy: Provided, That these foods are specifically designated
30	and manufactured for the treatment on inherited enzymatic disorders caused by single gene
31	defects involved in the metabolism of amino, organic and fatty acids and for severe allergic
32	conditions.
33	(d) The provisions of this section shall not apply to persons diagnosed with cystic fibrosis
34	or persons with an intolerance for lactose or soy.
	ARTICLE 25A. HEALTH MAINTENANCE ORGANIZATION ACT.
	§33-25A-8p. Coverage for inherited enzymatic disorders.
1	(a) A policy, plan or contract that is issued or renewed on or after January 1, 2018, and
2	that is subject to this section shall provide coverage for inherited enzymatic disorders caused by

3	single gene defects involved in the metabolism of amino, organic and fatty acids as well as severe
4	protein allergic conditions. This includes the following conditions if diagnosed as related to the
5	disorder by a physician licensed to practice in this state pursuant to either article three or fourteen
6	of chapter thirty of this code:
7	(1) Phenylketonuria;
8	(2) Maternal phenylketonuria;
9	(3) Maple syrup urine disease;
10	(4) Tyrosinemia;
11	(5) Homocystinuria;
12	(6) Histidinemia;
13	(7) Urea cycle disorders;
14	(8) Hyperlysinemia;
15	(9) Glutaric acidemias;
16	(10) Methylmalonic acidemia;
17	(11) Propionic academia;
18	(12) Immunoglobulin E and Nonimmunoglobulin E-medicated allergies to multiple food
19	proteins;
20	(13) Severe food protein induced enterocolitis syndrome;
21	(14) Eosinophilic disorders as evidenced by the results of a biopsy; and
22	(15) Impaired absorption of nutrients caused by disorders affecting the absorptive surface,
23	function, length and motility of the gastrointestinal tract.
24	(b) The coverage required by subsection (a) of this section is for medical foods for home
25	use for which a physician has issued a prescription and has declared them to be medically
26	necessary.
27	(c) For purposes of this section, medically necessary foods or medical foods shall mean
28	prescription metabolic formulas and their modular counterparts and amino acid-based elemental

CS for SB 526

- formulas obtained through a pharmacy: *Provided*, That these foods are specifically designated
 and manufactured for the treatment on inherited enzymatic disorders caused by single gene
 defects involved in the metabolism of amino, organic and fatty acids and for severe allergic
 conditions.
- (d) The provisions of this section shall not apply to persons diagnosed with cystic fibrosis
 or persons with an intolerance for lactose or soy.

NOTE: The purpose of this bill is to mandate insurance coverage for medical foods for inherited enzymatic disorders.

Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.